RGA study finds incretin drugs could reduce mortality up to 8.8%, so insurers should reassess assumptions.
Richard
Russell
Richard Russell
Richard Russell is vice president of biometric research within RGA’s global research & development team.
He holds a bachelor of science in biotechnology, a master of science in bioinformatics (with distinction), and a Ph.D. in statistics, all from Imperial College London. He has written more than 30 peer-reviewed publications in leading journals, including the Lancet, BMJ Open, PLOS One, and Annals of Actuarial Science.
